Pharmaceuticals & Biotech Canadian Community

Catalysts Federal rescheduling of marijuana from Schedule I to Schedule III of the Controlled Substances Act is an inevitability from a scientific and sociopolitical perspective within five years. Rescheduling will eliminate the application of the punitive s.Read more

Cybin’s aggressive analyst price targets make sense when you view the company through a true late-stage biotech lens rather than a speculative psychedelic stock. With more than US$225 million in cash after retiring all debt, Cybin is now one of the only fully funded companies in the entire sector with enough runway to complete multiple Phase 3 trials and deliver two major clinical readouts—Phase 2 CYB004 data in Q1 2026 and pivotal Phase 3 CYB003 results in Q4 2026.Read more

BioNxt is developing two platform technologies: a sublingual thin-film technology (ODF) for smart drug delivery and a novel chemotherapy platform in which the active ingredient is activated directly in the tumor—targeting and killing cancer cells while sparing healthy cells. The ODF technology is protected by a European broad patent (intention-to-grant, May 2025), covering a wide range of sublingual active ingredients and is being nationalized in key markets.Read more

Organigram Holdings Inc. has seen some significant developments in the past four months: ✓ Acquisition of Motif Labs: In December 2024, Organigram acquired Motif Labs, a Canadian cannabis company, for C$90 million upfront.Read more

It sounds like Cybin (CYBN) is gaining serious traction in the psychedelic therapy space! Guggenheim’s $35 price target is pretty aggressive, considering the stock is currently trading at a fraction of that.Read more

Key Takeaways Share repurchases and potential federal legalization could drive significant value creation, especially as institutional investment enters and market sentiment improves. Unique positioning in compliant THC beverages and premium branding set the stage for accelerated growth and expanded market share as the industry consolidates.Read more

Catalysts About Auxly Cannabis Group Auxly Cannabis Group is a Canadian cannabis company focused on branded products across dried flower, pre rolls and vapes, supported by cultivation and processing operations at Auxly Leamington. What are the underlying business or industry changes driving this perspective?Read more

Key Takeaways Reliance on international markets and regulatory uncertainty could threaten revenue growth and add financial volatility as legal or reimbursement environments shift. Intensifying price competition, ESG scrutiny, and rising operational costs may erode margin improvements and create challenges for sustained profitability.Read more

Key Takeaways Expanding internationally and innovating with premium and alternative products are expected to drive sustainable revenue growth and strengthen brand equity across key markets. Cost-cutting measures and operational improvements aim to enhance margins and position the company for success, particularly if U.S. federal legalization advances.Read more